Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Retina ; 43(3): 506-513, 2023 03 01.
Article in English | MEDLINE | ID: covidwho-2222837


PURPOSE: To investigate trends and the potential impact of the COVID-19 pandemic on the utilization of intravitreal antivascular endothelial growth factor (anti-VEGF) pharmaceuticals in an accountable care organization (ACO). METHODS: We retrospectively analyzed the Centers for Medicare and Medicaid Services beneficiary claims for all patients in the Houston Methodist Coordinated Care ACO registry during the years 2018, 2019, and 2020. RESULTS: Across the 3 years studied, a mean of 708 patients received anti-VEGF injections per year. The percentage of patients who received anti-VEGF injections decreased in each sequential year, with a steeper decline during the COVID-19 pandemic in the year 2020 (decrease by 0.4% from 2019 to 2020, P < 0.001; decrease by 0.2% from 2018 to 2019, P = 0.1453). The percentage of patients receiving bevacizumab of the total number of patients receiving any anti-VEGF treatment decreased (bevacizumab decreased by 6% from 2019 to 2020, P = 0.0174; decreased by 7% from 2018 to 2019, P = 0.0074). The COVID-19 pandemic did not seem to correlate with a change in the distribution of the specific anti-VEGF injection used. CONCLUSION: Despite the lower price which may correlate with value-based care, bevacizumab was the least used anti-VEGF treatment. COVID-19 correlated with a larger decrease in the utilization of all three anti-VEGF drugs.

COVID-19 , Ranibizumab , Humans , Aged , United States , Bevacizumab/therapeutic use , Ranibizumab/therapeutic use , Angiogenesis Inhibitors/therapeutic use , Vascular Endothelial Growth Factor A , Endothelial Growth Factors , Retrospective Studies , Pandemics , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Medicare , Pharmaceutical Preparations , Intravitreal Injections , Recombinant Fusion Proteins
Curr Opin Ophthalmol ; 31(5): 396-402, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-703541


PURPOSE OF REVIEW: To discuss key considerations involved in adapting an in-person ophthalmology conference to a virtual medium. RECENT FINDINGS: In 2020, several ophthalmological societies have held or are planning to hold virtual conferences in lieu of their previously scheduled in-person ophthalmology conference because of the coronavirus disease 2019 pandemic. The strategic meeting components attempted to be retained in these transitions include educational information disseminating, academic discussion with colleagues, sponsorships, and networking. Live-streamed components of a virtual conference may be entirely real time or may include a combination of both prerecorded and live-streamed components. A virtual meeting may offer either a single live-streamed program or several concurrent live-streamed programs from which attendees can choose. The availability of on-demand content, mechanisms for audience participation, avenues for industry interaction and contribution, registration costs, and continuing medical education credit availability vary between virtual meeting formats. SUMMARY: Transition of an in-person ophthalmology conference to a virtual format with retention of the inherent value associated with the meeting is possible and the experiences of societies executing this adaptation can be helpful for others entering this space. There are numerous considerations regarding meeting format and logistics to contemplate in light of each meeting's specific audience and objectives.

Betacoronavirus , Congresses as Topic/organization & administration , Coronavirus Infections/epidemiology , Ophthalmology/organization & administration , Pneumonia, Viral/epidemiology , Videoconferencing , COVID-19 , Humans , Pandemics , SARS-CoV-2 , Videoconferencing/organization & administration